2nd Quarter - Report

GEPHARDT GROUP GOVERNMENT AFFAIRS for HEALIANCE PHARMACEUTICALS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2012 $50,000 Replaced
2nd Quarter - Termination Amendment Jul 18, 2014 $50,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

innovative diabetes treatment

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

LobbyistCovered position, as disclosed
JANICE O'CONNELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

LobbyistCovered position, as disclosed
JANICE O'CONNELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Foreign Relations FOR

innovative diabetes treatment

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

LobbyistCovered position, as disclosed
JANICE O'CONNELL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.